207 related articles for article (PubMed ID: 26918730)
1. microRNAs are differentially regulated between MDM2-positive and negative malignant pleural mesothelioma.
Walter RF; Vollbrecht C; Werner R; Wohlschlaeger J; Christoph DC; Schmid KW; Mairinger FD
Oncotarget; 2016 Apr; 7(14):18713-21. PubMed ID: 26918730
[TBL] [Abstract][Full Text] [Related]
2. MDM2 is an important prognostic and predictive factor for platin-pemetrexed therapy in malignant pleural mesotheliomas and deregulation of P14/ARF (encoded by CDKN2A) seems to contribute to an MDM2-driven inactivation of P53.
Walter RF; Mairinger FD; Ting S; Vollbrecht C; Mairinger T; Theegarten D; Christoph DC; Schmid KW; Wohlschlaeger J
Br J Cancer; 2015 Mar; 112(5):883-90. PubMed ID: 25668009
[TBL] [Abstract][Full Text] [Related]
3. miRNA regulation is important for DNA damage repair and recognition in malignant pleural mesothelioma.
Mairinger FD; Werner R; Flom E; Schmeller J; Borchert S; Wessolly M; Wohlschlaeger J; Hager T; Mairinger T; Kollmeier J; Christoph DC; Schmid KW; Walter RFH
Virchows Arch; 2017 Jun; 470(6):627-637. PubMed ID: 28466156
[TBL] [Abstract][Full Text] [Related]
4. MicroRNA-215-5p Treatment Suppresses Mesothelioma Progression via the MDM2-p53-Signaling Axis.
Singh A; Bhattacharyya N; Srivastava A; Pruett N; Ripley RT; Schrump DS; Hoang CD
Mol Ther; 2019 Sep; 27(9):1665-1680. PubMed ID: 31227395
[TBL] [Abstract][Full Text] [Related]
5. Mdm2 protein expression is strongly associated with survival in malignant pleural mesothelioma.
Mairinger FD; Walter RF; Ting S; Vollbrecht C; Kollmeier J; Griff S; Hager T; Mairinger T; Christoph DC; Theegarten D; Schmid KW; Wohlschlaeger J
Future Oncol; 2014 May; 10(6):995-1005. PubMed ID: 24941985
[TBL] [Abstract][Full Text] [Related]
6. Secreted and Tissue miRNAs as Diagnosis Biomarkers of Malignant Pleural Mesothelioma.
Martínez-Rivera V; Negrete-García MC; Ávila-Moreno F; Ortiz-Quintero B
Int J Mol Sci; 2018 Feb; 19(2):. PubMed ID: 29462963
[TBL] [Abstract][Full Text] [Related]
7. MDM2 and HIF1alpha expression levels in different histologic subtypes of malignant pleural mesothelioma: correlation with pathological and clinical data.
Pasello G; Urso L; Mencoboni M; Grosso F; Ceresoli GL; Lunardi F; Vuljan SE; Bertorelle R; Sacchetto V; Ciminale V; Rea F; Favaretto A; Conte P; Calabrese F
Oncotarget; 2015 Dec; 6(39):42053-66. PubMed ID: 26544728
[TBL] [Abstract][Full Text] [Related]
8. Analysis of microRNA expression signatures in malignant pleural mesothelioma, pleural inflammation, and atypical mesothelial hyperplasia reveals common predictive tumorigenesis-related targets.
Ramírez-Salazar EG; Salinas-Silva LC; Vázquez-Manríquez ME; Gayosso-Gómez LV; Negrete-Garcia MC; Ramírez-Rodriguez SL; Chávez R; Zenteno E; Santillán P; Kelly-García J; Ortiz-Quintero B
Exp Mol Pathol; 2014 Dec; 97(3):375-85. PubMed ID: 25236577
[TBL] [Abstract][Full Text] [Related]
9. Synergistic targeting of malignant pleural mesothelioma cells by MDM2 inhibitors and TRAIL agonists.
Urso L; Cavallari I; Silic-Benussi M; Biasini L; Zago G; Calabrese F; Conte PF; Ciminale V; Pasello G
Oncotarget; 2017 Jul; 8(27):44232-44241. PubMed ID: 28562336
[TBL] [Abstract][Full Text] [Related]
10. Downregulated microRNAs in the differential diagnosis of malignant pleural mesothelioma.
Gee GV; Koestler DC; Christensen BC; Sugarbaker DJ; Ugolini D; Ivaldi GP; Resnick MB; Houseman EA; Kelsey KT; Marsit CJ
Int J Cancer; 2010 Dec; 127(12):2859-69. PubMed ID: 21351265
[TBL] [Abstract][Full Text] [Related]
11. Methylation-associated Silencing of microRNA-126 and its Host Gene EGFL7 in Malignant Pleural Mesothelioma.
Andersen M; Trapani D; Ravn J; Sørensen JB; Andersen CB; Grauslund M; Santoni-Rugiu E
Anticancer Res; 2015 Nov; 35(11):6223-9. PubMed ID: 26504055
[TBL] [Abstract][Full Text] [Related]
12. Two Different Serum MiRNA Signatures Correlate with the Clinical Outcome and Histological Subtype in Pleural Malignant Mesothelioma Patients.
Lamberti M; Capasso R; Lombardi A; Di Domenico M; Fiorelli A; Feola A; Perna AF; Santini M; Caraglia M; Ingrosso D
PLoS One; 2015; 10(8):e0135331. PubMed ID: 26262875
[TBL] [Abstract][Full Text] [Related]
13. High RRM1 Expression Is Associated with Adverse Outcome in Patients with Cisplatin/Vinorelbine-treated Malignant Pleural Mesothelioma.
Zimling ZG; Santoni-Rugiu E; Bech C; Sørensen JB
Anticancer Res; 2015 Dec; 35(12):6731-8. PubMed ID: 26637889
[TBL] [Abstract][Full Text] [Related]
14. Circulating microRNAs found dysregulated in ex-exposed asbestos workers and pleural mesothelioma patients as potential new biomarkers.
Bononi I; Comar M; Puozzo A; Stendardo M; Boschetto P; Orecchia S; Libener R; Guaschino R; Pietrobon S; Ferracin M; Negrini M; Martini F; Bovenzi M; Tognon M
Oncotarget; 2016 Dec; 7(50):82700-82711. PubMed ID: 27716620
[TBL] [Abstract][Full Text] [Related]
15. Signal Transducer and Activator of Transcription 1 (STAT1) Knock-down Induces Apoptosis in Malignant Pleural Mesothelioma.
Arzt L; Halbwedl I; Gogg-Kamerer M; Popper HH
Pathol Oncol Res; 2017 Jul; 23(3):595-605. PubMed ID: 27987139
[TBL] [Abstract][Full Text] [Related]
16. Deregulation of miRNAs in malignant pleural mesothelioma is associated with prognosis and suggests an alteration of cell metabolism.
De Santi C; Melaiu O; Bonotti A; Cascione L; Di Leva G; Foddis R; Cristaudo A; Lucchi M; Mora M; Truini A; Tironi A; Murer B; Boldorini R; Cipollini M; Gemignani F; Gasparini P; Mutti L; Landi S
Sci Rep; 2017 Jun; 7(1):3140. PubMed ID: 28600498
[TBL] [Abstract][Full Text] [Related]
17. Prognostic and Therapeutic Implications of MicroRNA in Malignant Pleural Mesothelioma.
Truini A; Coco S; Genova C; Mora M; Dal Bello MG; Vanni I; Alama A; Rijavec E; Barletta G; Biello F; Maggioni C; Grossi F
Microrna; 2016; 5(1):12-18. PubMed ID: 26817512
[TBL] [Abstract][Full Text] [Related]
18. Diagnostic potential of miR-126, miR-143, miR-145, and miR-652 in malignant pleural mesothelioma.
Andersen M; Grauslund M; Ravn J; Sørensen JB; Andersen CB; Santoni-Rugiu E
J Mol Diagn; 2014 Jul; 16(4):418-30. PubMed ID: 24912849
[TBL] [Abstract][Full Text] [Related]
19. ZIC1 is silenced and has tumor suppressor function in malignant pleural mesothelioma.
Cheng YY; Kirschner MB; Cheng NC; Gattani S; Klebe S; Edelman JJ; Vallely MP; McCaughan BC; Jin HC; van Zandwijk N; Reid G
J Thorac Oncol; 2013 Oct; 8(10):1317-28. PubMed ID: 24457242
[TBL] [Abstract][Full Text] [Related]
20. Malignant pleural mesothelioma and mesothelial hyperplasia: A new molecular tool for the differential diagnosis.
Bruno R; Alì G; Giannini R; Proietti A; Lucchi M; Chella A; Melfi F; Mussi A; Fontanini G
Oncotarget; 2017 Jan; 8(2):2758-2770. PubMed ID: 27835874
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]